Our Mission

To provide more effective treatment options for patients with mucin related diseases

Mucpharm is a specialised company focused on the treatment of mucin-containing and secreting conditions. Our company was established by a group of clinicians and scientists, who specialise in treating patients with advanced cancers of the peritoneum.

Mucpharm’s aim is to develop BromAc® for a rare disease in oncology, known as pseudomyxoma peritonei. We have grown and continue to focus on the treatment of mucin-containing and secreting cancers and other disease conditions, with BromAc® as our lead compound.

Many diseases involve mucin. Mucin is a barrier to cancer and targeted therapies due to promoting chemoresistance, invasiveness and metastasis. We have demonstrated in a number of studies that BromAc® removes mucin from cancer cells, sensitizing them to chemotherapy and other treatment agents. The efficacy of BromAc® in advanced cancers is being explored in phase 2 studies.

The role of mucin in a range of respiratory diseases is already established, leading to a decline in respiratory function and secondary infections in some cases. The role of BromAc® in these conditions is being investigated in clinical trials.

We seek to continue to grow scientific and clinical research based in Australia and engage in global partnerships to strengthen the development of products for unmet medical need and rare disease areas

Our Team

Having worked together for many years, we share common goals and aspirations to develop new and improved treatments for difficult to treat cancers, respiratory diseases and infections. Our goal is to improve the quality of life and overall survival of patients with rare diseases and unmet medical need areas and continue to grow as a research and pharmaceutical development team.